Clinical Trials

  • Principal Investigator:

    Philip L. De Jager, MD, PhD
    This study aims to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed at the New York Brain Bank. The study is primarily online, with online cognitive evaluations every three years. A subset of...
  • Principal Investigator:

    Philip L. De Jager, MD, PhD
    The Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed...
  • Principal Investigator:

    Philip L. De Jager, MD, PhD
    MS Genetics aims to better understand the genetic component of demyelinating diseases by doing genetic testing on blood samples of participants. This study involves a once time blood draw and completion of questionnaires spread out over a couple of years in hopes to better understand the genes that makes one predisposed to Multiple Sclerosis and various other demyelinating diseases.
  • Principal Investigator:

    Christiane Reitz, MD, PhD
    We are recruiting families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide information on...
  • Principal Investigator:

    Christiane Reitz, MD, PhD
    We are recruiting families or individuals with members above the age of 70 who do not have dementia or are not experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will...
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of the study is to evaluate the tolerability of a ketogenic diet in conjunction with metformin in people with malignant glioma. The study doctors will try to determine if maintaining the ketogenic diet with metformin will have any effect on your tumor.
  • Principal Investigator:

    Philip L. De Jager, MD, PhD
    Genes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of biological specimen, including saliva and blood, as well as the completion of questionnaires regarding personal and family health history, diet, and other environmental exposures. The goal of this study is to use these data to develop and test an algorithm predicting risk of MS onset that...
  • Principal Investigator:

    Philip L. De Jager, MD, PhD
    Genes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of biological specimen, including saliva and blood, as well as the completion of questionnaires regarding personal and family health history, diet, and other environmental exposures. The goal of this study is to use these data to develop and test an algorithm predicting risk of MS onset that...
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    Optune is a portable, battery operated device that generates TTFields at a specific frequency. The TTFields are delivered to the brain through 4 sticky bandages (which hold ceramic discs) that are placed on the surface of the head (called arrays). The arrays create electric forces within the brain that disrupt cancer cell division. Optunes TTFields are a novel type of cancer treatment that have been shown in laboratory studies to slow the growth of tumors, without causing significant side effects. In addition, the use of TTFields as a cancer treatment has been tested in numerous studies of...
  • Principal Investigator:

    Aya Haggiagi, MD
    This study is being done to answer the following question: Can we add newer drugs to traditional chemotherapy combinations used for treatment of primary central nervous system lymphoma? We are doing this study because we want to find out whether rituximab, methotrexate, lenalidomide, and nivolumab can be safely combined for treatment of primary Central Nervous System (CNS) lymphoma and which dose is the most adequate when they are used together. Lenalidomide and nivolumab have demonstrated activity in primary CNS lymphoma but are still considered investigational in this setting and have not...

Pages